{
    "organizations": [],
    "uuid": "49cb17d817ea5aabf031a06afbc634b8d9577f2a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-knight-therapeutics-announces-cana/brief-knight-therapeutics-announces-canadian-regulatory-approval-for-probuphine-for-opioid-drug-dependence-idUSFWN1RX0ZK",
    "ord_in_thread": 0,
    "title": "BRIEF-Knight Therapeutics Announces Canadian Regulatory Approval For Probuphine For Opioid Drug Dependence",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20 (Reuters) - Knight Therapeutics Inc:\n* KNIGHT THERAPEUTICS ANNOUNCES CANADIAN REGULATORY APPROVAL FOR PROBUPHINEâ„¢ FOR OPIOID DRUG DEPENDENCE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-21T04:05:00.000+03:00",
    "crawled": "2018-04-21T18:11:20.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "knight",
        "therapeutic",
        "inc",
        "knight",
        "therapeutic",
        "announces",
        "canadian",
        "regulatory",
        "approval",
        "opioid",
        "drug",
        "dependence",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}